Trial started· ClinicalTrials.gov
GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
Semaglutide History and Updates
250 events · 2007 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
45
FDA Approvals
1
Label Revisions
1,789
Trial Milestones
9
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-12Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for Semaglutide since 2007, drawn from openFDA, ClinicalTrials.gov, and PubMed.
All published updates (61)
2026
- Results postedSemaglutide + Insulin Icodec for Type 2 Diabetes Shows HbA1c Reduction· Jun 3, 2026
- Label revisionOzempic Label Adds Boxed Warning for Thyroid C-Cell Tumors· May 19, 2026
- Results postedSemaglutide Achieves -12.2% Weight Loss in Overweight/Obesity Study· May 18, 2026
- Results postedSemaglutide + Lower Insulin Glargine Reduces HbA1c, Weight in T2D· May 11, 2026
- Results postedSemaglutide Oral Tablet Shows Significant Weight Loss in Obesity Trial· May 7, 2026
- Primary completionSemaglutide Biosimilar Trial vs. Wegovy in Obesity Completes Phase 3· Apr 30, 2026
- Results postedSemaglutide 7.2 mg Shows Superior Weight Loss in Obesity, Type 2 Diabetes· Apr 27, 2026
- Results postedSemaglutide for Obesity: Phase 3 Trial Shows Significant Weight Loss vs. Placebo· Apr 23, 2026
- Results postedTrial results posted: NCT05144984· Apr 9, 2026
- Primary completionSemaglutide Trial for Klinefelter Syndrome Reaches Primary Completion· Apr 1, 2026
- Primary completionSemaglutide Phase 3 Trial in Type 2 Diabetes Reaches Primary Completion· Mar 20, 2026
- FDA approval (supplemental)Wegovy (semaglutide) FDA Approves Supplemental Efficacy Application· Mar 19, 2026
- Results postedSemaglutide Oral 25 mg Shows Significant Weight Loss in Overweight/Obesity· Feb 25, 2026
- Results postedSemaglutide Alzheimer's Trial Posts Gene Expression Changes in CSF and Blood· Feb 24, 2026
- Results postedSemaglutide Reduces Abdominal and Total Body Fat in HIV Lipohypertrophy· Feb 17, 2026
- Results postedSemaglutide Reduces Weight, Cravings, and Food Intake in Obesity Trial· Feb 10, 2026
- Results postedSemaglutide in CFRD Pilot Study Shows Weight, BMI, A1c Reduction· Jan 21, 2026
- Results postedSemaglutide in Type 2 Diabetes, CKD: No Significant Impact on Kidney Oxygenation· Jan 14, 2026
- Results postedSemaglutide Plus NNC0165-1875 Reduces Body Weight in Obesity Study· Jan 8, 2026
- Pivotal publicationSemaglutide: ACHIEVE-3 Study Compares Oral Orforglipron Efficacy· Jan 1, 2026
- Pivotal publicationSemaglutide Phase 3 EVOKE/EVOKE+ Trial Results in Early Alzheimer's Disease…· Jan 1, 2026
2025
- FDA approvalWegovy (Semaglutide) Approved by FDA as a New Dosage Form· Dec 22, 2025
- Results postedSemaglutide in Obesity Trial: Tirzepatide Shows Superior Weight Reduction· Nov 26, 2025
- Results postedSemaglutide Combination Therapy Shows Significant NASH Resolution in Cirrhosis· Nov 26, 2025
- Results postedSemaglutide Shows Greater Weight Reduction in Adolescent PCOS/Obesity Trial· Nov 25, 2025
- FDA approval (supplemental)Wegovy (Semaglutide) Gains FDA Supplemental Approval for Efficacy· Nov 21, 2025
- Results postedSemaglutide Shows Lower Dementia Risk vs. DPP4 Inhibitors in Diabetes Patients· Nov 10, 2025
- FDA approval (supplemental)Ozempic (Semaglutide) Receives FDA Supplemental Efficacy Approval· Oct 17, 2025
- Primary completionSemaglutide Phase 3 Trial for Pediatric Obesity Completes Primary Data…· Oct 15, 2025
- Results postedOral Semaglutide Reduces Major Adverse CV Events in Type 2 Diabetes· Sep 22, 2025
- Primary completionSemaglutide EVOKE Trial for Early Alzheimer's Disease Completes Primary Phase· Sep 16, 2025
- Primary completionSemaglutide EVOKE Plus Trial for Early Alzheimer's Disease Reaches Primary…· Sep 15, 2025
- Results postedSemaglutide Shows Increased EPC Gene Expression in Type 2 Diabetes· Sep 9, 2025
- Primary completionSemaglutide Trial for Type 2 Diabetes Completes Primary Phase· Aug 30, 2025
- Primary completionSemaglutide Trial for Obesity Management Completes Primary Phase· Aug 27, 2025
- FDA approval (supplemental)Wegovy (semaglutide) FDA Approves Supplemental Efficacy Application· Aug 15, 2025
- Results postedSemaglutide Adjunct Therapy Hits Composite Endpoint in Type 1 Diabetes· Aug 12, 2025
- Results postedSemaglutide Phase 2 Trial Results Posted for Nicotine Addiction· Jul 18, 2025
- Results postedSemaglutide with Bimagrumab Shows Enhanced Weight Loss in Obesity· Jul 18, 2025
- Results postedSemaglutide Improves Walking Distance, Quality of Life in PAD with T2D· Jul 8, 2025
- Primary completionSemaglutide Phase 3 Trial for Type 2 Diabetes Mellitus Completes· May 14, 2025
- Results postedSemaglutide Trial Shows Greater Lean Body Mass Reduction in Older Adults· May 4, 2025
- Primary completionSemaglutide Phase 3 Trial for Pediatric Type 2 Diabetes Completes· Apr 29, 2025
- Results postedSemaglutide Phase 2 Trial Results Posted for Obesity in Elderly Patients· Apr 17, 2025
- Primary completionSemaglutide + Insulin Icodec Phase 3 for Type 2 Diabetes Reduces HbA1c· Apr 14, 2025
- Results postedSemaglutide Obesity Trial in Asia Hits Primary Endpoint with -16.4% Weight Loss· Apr 3, 2025
- Primary completionSemaglutide Phase 3 Trial for Overweight and Obesity Reaches Primary Completion· Apr 2, 2025
- Primary completionSemaglutide Trial for Poor Weight-Loss After Bariatric Surgery Completes Phase 3· Mar 31, 2025
- Results postedSemaglutide for Alcohol Use Disorder: Trial Shows Reduced Alcohol Consumption· Mar 24, 2025
- Results postedSemaglutide for Type 2 Diabetes and CKD: Renal Events Reduced vs. Placebo· Mar 20, 2025
- Primary completionSemaglutide SUSTAIN OPTIMIZE Trial for Type 2 Diabetes Completes Primary Phase· Mar 5, 2025
- Primary completionSemaglutide Trial for Weight Loss in Bangladeshi Adults Reaches Primary…· Feb 28, 2025
- Results postedSemaglutide Reduces HbA1c by 1.6% and Weight by 5.3 kg in Type 2 Diabetes· Feb 10, 2025
- Pivotal publicationSemaglutide: Oral 25 mg Dose for Overweight or Obesity Results Published· Jan 1, 2025
- Pivotal publicationSemaglutide Study Compares Walking Capacity in PAD and Type 2 Diabetes· Jan 1, 2025
- Pivotal publicationSemaglutide Phase 3 Trial Results Published for Metabolic…· Jan 1, 2025
- Pivotal publicationSemaglutide Combination Shows Weight Loss in Type 2 Diabetes and Obesity· Jan 1, 2025
- Pivotal publicationSemaglutide Cardiovascular Outcomes in High-Risk Type 2 Diabetes Published· Jan 1, 2025
- Pivotal publicationSemaglutide SELECT Trial Analysis on Cardiovascular Outcomes Published· Jan 1, 2025
- Pivotal publicationSemaglutide Coadministration with Cagrilintide in Overweight/Obesity Published· Jan 1, 2025
2024
- Primary completionSemaglutide Phase 3 for PAD and T2D Improves Walking Distance and Quality of…· Jun 5, 2024
Upcoming & expected milestones
Primary completion· ClinicalTrials.gov
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in Peop
Primary completion· ClinicalTrials.gov
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level i
Primary completion· ClinicalTrials.gov
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Wheth
Primary completion· ClinicalTrials.gov
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
Primary completion· ClinicalTrials.gov
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
Primary completion· ClinicalTrials.gov
Lifestyle Counseling and Medication for Adolescent Weight Management
Primary completion· ClinicalTrials.gov
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Primary completion· ClinicalTrials.gov
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Trial started· ClinicalTrials.gov
Semaglutide (Wegovy) Treatment for Trichotillomania
Trial started· ClinicalTrials.gov
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
Primary completion· ClinicalTrials.gov
Semaglutide for Post-Smoking Cessation Weight Management
Trial started· ClinicalTrials.gov
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Effi
Trial started· ClinicalTrials.gov
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weigh
Primary completion· ClinicalTrials.gov
Lifestyle Counseling and Medication for Adolescent Weight Management
Primary completion· ClinicalTrials.gov
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
Primary completion· ClinicalTrials.gov
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
Primary completion· ClinicalTrials.gov
Effect of Semaglutide in Patients With Psoriasis and Obesity
Primary completion· ClinicalTrials.gov
Semaglutide for Smoking Cessation in Patients With Diabetes
Primary completion· ClinicalTrials.gov
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
Primary completion· ClinicalTrials.gov
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
Primary completion· ClinicalTrials.gov
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
Primary completion· ClinicalTrials.gov
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
Trial started· ClinicalTrials.gov
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
Primary completion· ClinicalTrials.gov
The Effect of Semaglutide on the Intestinal Flora in Obesity
Primary completion· ClinicalTrials.gov
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
Trial started· ClinicalTrials.gov
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Di
Primary completion· ClinicalTrials.gov
Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health
Primary completion· ClinicalTrials.gov
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral
Primary completion· ClinicalTrials.gov
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Primary completion· ClinicalTrials.gov
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
Primary completion· ClinicalTrials.gov
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin Wi
Primary completion· ClinicalTrials.gov
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
Primary completion· ClinicalTrials.gov
Semaglutide for Helping Opioid Recovery
Primary completion· ClinicalTrials.gov
Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)
Primary completion· ClinicalTrials.gov
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Primary completion· ClinicalTrials.gov
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
Primary completion· ClinicalTrials.gov
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
Primary completion· ClinicalTrials.gov
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
Trial started· ClinicalTrials.gov
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Primary completion· ClinicalTrials.gov
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidn
Primary completion· ClinicalTrials.gov
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
Primary completion· ClinicalTrials.gov
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabe
Primary completion· ClinicalTrials.gov
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
Primary completion· ClinicalTrials.gov
Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus
Trial started· ClinicalTrials.gov
GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
Primary completion· ClinicalTrials.gov
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Part
Trial started· ClinicalTrials.gov
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
Trial started· ClinicalTrials.gov
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
Primary completion· ClinicalTrials.gov
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Typ
Past events
2026
Trial registered· ClinicalTrials.gov
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Trial registered· ClinicalTrials.gov
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Trial registered· ClinicalTrials.gov
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
Trial registered· ClinicalTrials.gov
Weight Loss in Adults Using Semaglutide (Real-world Study)
Trial registered· ClinicalTrials.gov
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
Results posted· ClinicalTrials.gov
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level i
Primary completion· ClinicalTrials.gov
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated
Trial registered· ClinicalTrials.gov
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
Trial registered· ClinicalTrials.gov
Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Su
Trial registered· ClinicalTrials.gov
Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.
Trial registered· ClinicalTrials.gov
GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
Trial started· ClinicalTrials.gov
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
Primary completion· ClinicalTrials.gov
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
Primary completion· ClinicalTrials.gov
Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.
Trial started· ClinicalTrials.gov
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
Primary completion· ClinicalTrials.gov
Weight Loss in Adults Using Semaglutide (Real-world Study)
Primary completion· ClinicalTrials.gov
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Trial started· ClinicalTrials.gov
Semaglutide (Wegovy) Treatment for Trichotillomania
Primary completion· ClinicalTrials.gov
Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
Trial started· ClinicalTrials.gov
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
Primary completion· ClinicalTrials.gov
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
Primary completion· ClinicalTrials.gov
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFp
Trial registered· ClinicalTrials.gov
GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
Trial registered· ClinicalTrials.gov
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
Primary completion· ClinicalTrials.gov
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Trial started· ClinicalTrials.gov
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without
Trial started· ClinicalTrials.gov
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and
Trial registered· ClinicalTrials.gov
Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes
Label revision· FDA
WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, incl
Primary completion· ClinicalTrials.gov
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients W
Trial registered· ClinicalTrials.gov
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
Results posted· ClinicalTrials.gov
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
Trial registered· ClinicalTrials.gov
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
Trial registered· ClinicalTrials.gov
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
Trial registered· ClinicalTrials.gov
Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
Primary completion· ClinicalTrials.gov
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFp
Results posted· ClinicalTrials.gov
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine
Results posted· ClinicalTrials.gov
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS
Trial registered· ClinicalTrials.gov
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
Trial registered· ClinicalTrials.gov
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without
Trial started· ClinicalTrials.gov
Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health
Trial started· ClinicalTrials.gov
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Primary completion· ClinicalTrials.gov
DUTCH Weight Control in Atrial Fibrillation Study
Trial started· ClinicalTrials.gov
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
Trial started· ClinicalTrials.gov
Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes
Trial started· ClinicalTrials.gov
Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
Primary completion· ClinicalTrials.gov
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
Trial started· ClinicalTrials.gov
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
Primary completion· ClinicalTrials.gov
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
Trial started· ClinicalTrials.gov
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
Trial started· ClinicalTrials.gov
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
Primary completion· ClinicalTrials.gov
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
Trial registered· ClinicalTrials.gov
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Wheth
Results posted· ClinicalTrials.gov
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
Results posted· ClinicalTrials.gov
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
Trial registered· ClinicalTrials.gov
Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)
Primary completion· ClinicalTrials.gov
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Trial started· ClinicalTrials.gov
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
Trial started· ClinicalTrials.gov
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Trial registered· ClinicalTrials.gov
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Trial registered· ClinicalTrials.gov
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
Trial started· ClinicalTrials.gov
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Results posted· ClinicalTrials.gov
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
Trial started· ClinicalTrials.gov
Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)
Trial started· ClinicalTrials.gov
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Wheth
Trial registered· ClinicalTrials.gov
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
Trial registered· ClinicalTrials.gov
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
Trial registered· ClinicalTrials.gov
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
Trial started· ClinicalTrials.gov
A Study of CS060380 Tablets in Patients With MASH and Obesity
Primary completion· ClinicalTrials.gov
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
Primary completion· ClinicalTrials.gov
Young Adults With Early-onset Obesity Treated With Semaglutide
Trial registered· ClinicalTrials.gov
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
Trial started· ClinicalTrials.gov
Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement
Trial started· ClinicalTrials.gov
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
Primary completion· ClinicalTrials.gov
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Ri
Primary completion· ClinicalTrials.gov
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Trial started· ClinicalTrials.gov
Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
Trial started· ClinicalTrials.gov
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
Trial started· ClinicalTrials.gov
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
Primary completion· ClinicalTrials.gov
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
Trial started· ClinicalTrials.gov
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist
Trial registered· ClinicalTrials.gov
Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
Trial registered· ClinicalTrials.gov
Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes
Primary completion· ClinicalTrials.gov
A Study of BGM0504 in Participants with Type 2 Diabetes
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Efficacy.
Trial registered· ClinicalTrials.gov
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
Trial started· ClinicalTrials.gov
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
Trial registered· ClinicalTrials.gov
A Study of CS060380 Tablets in Patients With MASH and Obesity
Trial registered· ClinicalTrials.gov
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Trial registered· ClinicalTrials.gov
Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)
Trial started· ClinicalTrials.gov
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
Primary completion· ClinicalTrials.gov
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated
Trial registered· ClinicalTrials.gov
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist
Trial started· ClinicalTrials.gov
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Trial started· ClinicalTrials.gov
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
Primary completion· ClinicalTrials.gov
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
Primary completion· ClinicalTrials.gov
Semaglutide 2.4mg for Low Responders After Bariatric Surgery
Primary completion· ClinicalTrials.gov
Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
Trial started· ClinicalTrials.gov
Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
Primary completion· ClinicalTrials.gov
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
Primary completion· ClinicalTrials.gov
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
Results posted· ClinicalTrials.gov
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
Trial registered· ClinicalTrials.gov
GLP-1 RA for Stage 1 Type 1 Diabetes
Trial registered· ClinicalTrials.gov
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
Results posted· ClinicalTrials.gov
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
Trial registered· ClinicalTrials.gov
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
Primary completion· ClinicalTrials.gov
Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and
Trial registered· ClinicalTrials.gov
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
Trial registered· ClinicalTrials.gov
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Trial registered· ClinicalTrials.gov
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Results posted· ClinicalTrials.gov
Effects of Semaglutide in HIV-Associated Lipohypertrophy
Trial started· ClinicalTrials.gov
The Evira Study: Additional Support During Obesity Treatment
Trial registered· ClinicalTrials.gov
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weigh
Trial started· ClinicalTrials.gov
Incretin Microdosing for Cardiometabolic Health in People With HIV
Trial registered· ClinicalTrials.gov
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
Results posted· ClinicalTrials.gov
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Trial registered· ClinicalTrials.gov
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and
Trial registered· ClinicalTrials.gov
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response
Trial registered· ClinicalTrials.gov
Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
Trial registered· ClinicalTrials.gov
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFp
Trial started· ClinicalTrials.gov
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Di
Trial started· ClinicalTrials.gov
The Effect of Semaglutide on the Intestinal Flora in Obesity
Trial started· ClinicalTrials.gov
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response
Trial started· ClinicalTrials.gov
Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination
Primary completion· ClinicalTrials.gov
Triple Therapy in T1DM
Trial started· ClinicalTrials.gov
Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus
Primary completion· ClinicalTrials.gov
Anti-obesity Pharmacotherapy and Inflammation
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
Trial registered· ClinicalTrials.gov
Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
Trial started· ClinicalTrials.gov
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Trial started· ClinicalTrials.gov
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFp
Trial registered· ClinicalTrials.gov
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
Primary completion· ClinicalTrials.gov
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
Trial started· ClinicalTrials.gov
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostat
Results posted· ClinicalTrials.gov
Semaglutide in CFRD
Trial started· ClinicalTrials.gov
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
Trial started· ClinicalTrials.gov
Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
Primary completion· ClinicalTrials.gov
The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial
Trial started· ClinicalTrials.gov
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
Trial started· ClinicalTrials.gov
Glutide for Ending Methamphetamine
Trial started· ClinicalTrials.gov
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder
Trial started· ClinicalTrials.gov
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
Results posted· ClinicalTrials.gov
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
Results posted· ClinicalTrials.gov
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Dis
Results posted· ClinicalTrials.gov
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
Trial started· ClinicalTrials.gov
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Trial registered· ClinicalTrials.gov
Incretin Microdosing for Cardiometabolic Health in People With HIV
Trial registered· ClinicalTrials.gov
The Effect of Semaglutide on the Intestinal Flora in Obesity
Trial registered· ClinicalTrials.gov
Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity
Trial started· ClinicalTrials.gov
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
Trial started· ClinicalTrials.gov
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
Trial registered· ClinicalTrials.gov
Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
Trial registered· ClinicalTrials.gov
GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM
Primary completion· ClinicalTrials.gov
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Pivotal publication· PubMed
ACHIEVE-3 — A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Primary completion· ClinicalTrials.gov
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
Pivotal publication· PubMed
EVOKE Plus — A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
Trial started· ClinicalTrials.gov
Improved Treatment and Monitoring of Alzheimer's Disease
2025
Trial started· ClinicalTrials.gov
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Typ
Primary completion· ClinicalTrials.gov
Genetics of the Acute Response to Oral Semaglutide
Primary completion· ClinicalTrials.gov
Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea
Trial started· ClinicalTrials.gov
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
Trial started· ClinicalTrials.gov
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do No
Trial started· ClinicalTrials.gov
Epicardial Cardiac Fat-CT (EPIC-CT)
Trial started· ClinicalTrials.gov
Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity
Primary completion· ClinicalTrials.gov
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
Primary completion· ClinicalTrials.gov
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
Trial started· ClinicalTrials.gov
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
Trial registered· ClinicalTrials.gov
Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
FDA approval· FDA
Sponsor: NOVO. Class: Type 3 - New Dosage Form.
Trial registered· ClinicalTrials.gov
Epicardial Cardiac Fat-CT (EPIC-CT)
Recall· FDA
Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4501-14
Trial registered· ClinicalTrials.gov
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
Primary completion· ClinicalTrials.gov
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes M
Trial registered· ClinicalTrials.gov
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
Trial registered· ClinicalTrials.gov
Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination
Recall· FDA
Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4505-14
Primary completion· ClinicalTrials.gov
A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real
Trial registered· ClinicalTrials.gov
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
Trial registered· ClinicalTrials.gov
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do No
Trial registered· ClinicalTrials.gov
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Di
Trial started· ClinicalTrials.gov
Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study
Trial registered· ClinicalTrials.gov
Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea
Trial registered· ClinicalTrials.gov
Semaglutide (Wegovy) Treatment for Trichotillomania
Trial registered· ClinicalTrials.gov
WEgovy Real World Assessment of Weight Loss in Korea
Trial registered· ClinicalTrials.gov
Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study
Trial registered· ClinicalTrials.gov
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
Trial registered· ClinicalTrials.gov
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level i
Primary completion· ClinicalTrials.gov
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Primary completion· ClinicalTrials.gov
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2
Trial started· ClinicalTrials.gov
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level i
Trial started· ClinicalTrials.gov
GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis
Trial started· ClinicalTrials.gov
Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
Primary completion· ClinicalTrials.gov
Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fract
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.